Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021

DelveInsights, Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Fibrodysplasia ossificans progressiva pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Fibrodysplasia ossificans progressiva Understanding
Fibrodysplasia ossificans progressiva: Overview
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the bodys skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible. Patients with FOP have malformed big toes that are present at birth (congenital). Other skeletal malformations may occur. The abnormal episodic development of bone at multiple soft tissue sites frequently leads to stiffness in affected areas, limited movement, and eventual ankylosis (fusion) of affected joints (neck, back, shoulders, elbows, hips knees, wrists, ankles, jaw often in that order).

"Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fibrodysplasia ossificans progressiva pipeline landscape is provided which includes the disease overview and Fibrodysplasia ossificans progressiva treatment guidelines. The assessment part of the report embraces, in depth Fibrodysplasia ossificans progressiva commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibrodysplasia ossificans progressiva collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Fibrodysplasia ossificans progressiva R&D. The therapies under development are focused on novel approaches to treat/improve Fibrodysplasia ossificans progressiva.

Fibrodysplasia ossificans progressiva Emerging Drugs Chapters
This segment of the Fibrodysplasia ossificans progressiva report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fibrodysplasia ossificans progressiva Emerging Drugs
Palovarotene: Ipsen
Palovarotene is a RAR agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene, which had rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder, was acquired by Ipsen through the acquisition in April 2019 of Clementia Pharmaceuticals.

BLU-782: Blueprint Medicines
BLU-782 is an orally administered, potent and highly selective ALK2 inhibitor. It was designed specifically to target the underlying genetic driver of fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling and ultimately life-shortening genetic disease.
Further product details are provided in the report..

Fibrodysplasia ossificans progressiva: Therapeutic Assessment
This segment of the report provides insights about the different Fibrodysplasia ossificans progressiva drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Fibrodysplasia ossificans progressiva
There are approx. 10+ key companies which are developing the therapies for Fibrodysplasia ossificans progressiva. The companies which have their Fibrodysplasia ossificans progressiva drug candidates in the most advanced stage, i.e. preregistrtion include, Ipsen.

Phases
DelveInsights report covers around 10+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Fibrodysplasia ossificans progressiva pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fibrodysplasia ossificans progressiva: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibrodysplasia ossificans progressiva therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibrodysplasia ossificans progressiva drugs.

Fibrodysplasia ossificans progressiva Report Insights
Fibrodysplasia ossificans progressiva Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Fibrodysplasia ossificans progressiva Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Fibrodysplasia ossificans progressiva drugs?
How many Fibrodysplasia ossificans progressiva drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibrodysplasia ossificans progressiva?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Fibrodysplasia ossificans progressiva therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Fibrodysplasia ossificans progressiva and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Ipsen
Blueprint Medicines
Regeneron Pharmaceuticals
Daiichi Sankyo, Inc.
AstraZeneca
Incyte Corporation
Keros Therapeutics
BioCryst Pharmaceuticals

Key Products
Palovarotene
BLU 782
REGN2477
DS-6016a
AZD0530
INCB 000928
KER 047
BCX 9250
BCX 9499

Introduction
Executive Summary
Fibrodysplasia ossificans progressiva: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Fibrodysplasia ossificans progressiva DelveInsights Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Palovarotene: Ipsen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..

Mid Stage Products (Phase II)
Comparative Analysis
BLU 782: Blueprint Medicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
DS 6016: Daiichi Sankyo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Fibrodysplasia ossificans progressiva Key Companies
Fibrodysplasia ossificans progressiva Key Products
Fibrodysplasia ossificans progressiva- Unmet Needs
Fibrodysplasia ossificans progressiva- Market Drivers and Barriers
Fibrodysplasia ossificans progressiva- Future Perspectives and Conclusion
Fibrodysplasia ossificans progressiva Analyst Views
Fibrodysplasia ossificans progressiva Key Companies
Appendix

List Of Tables

Table 1 Total Products for Fibrodysplasia ossificans progressiva
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Fibrodysplasia ossificans progressiva
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available